4 news items
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
:Meichiel KeenanDirector, Investor Relations and Corporate Communicationsmedia@fibrogen.com
FibroGen to Report First Quarter 2024 Financial Results
FGEN
29 Apr 24
with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
24 Apr 24
Relations and Corporate Communications
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
@fibrogen.com Media:Meichiel KeenanDirector, Investor Relations and Corporate Communications
- Prev
- 1
- Next